Roche Holding's Ocrevus Will Likely Continue To Drive Earnings Growth In The Near Term

Roche Holding (NASDAQ:RHHBY) recently posted its Q3 results, which were more or less in line with estimates. The company's overall revenues grew 7%, led by a continued ramp up in Ocrevus, and Perjeta sales. However, Rituxan sales continued to see pressure in Europe, and the global sales were down...